WO2026093842 - A PROCESS FOR PRODUCING FC-FUSION PROTEIN IN MAMMALIAN CELL CULTURE
National phase entry is expected:
Publication Number
WO/2026/093842
Publication Date
07.05.2026
International Application No.
PCT/IB2025/060478
International Filing Date
15.10.2025
Title **
[English]
A PROCESS FOR PRODUCING FC-FUSION PROTEIN IN MAMMALIAN CELL CULTURE
[French]
PROCÉDÉ DE PRODUCTION DE PROTÉINE DE FUSION FC DANS LA CULTURE DE CELLULES DE MAMMIFÈRE
Applicants **
KASHIV BIOSCIENCES, LLC
Inventors
DEVASHRI, Nayan Niranjan
VAISHNAV, Parth Hitarthbhai
Priority Data
202421083014
30.10.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3374 | |
| EPO | Filing, Examination, Granting | 33927 | |
| Japan | Filing, Examination, Granting | 3328 | |
| South Korea | Filing, Examination, Granting | 4663 | |
| USA | Filing, Examination, Granting | 13310 |
Total:
58,602
Contact Us
Abstract[English]
The present disclosure relates to an improved process to control product quality parameters selected from total sialyation profile and increased main peak percentage of the Fc-Fusion protein specifically CTLA4-IgG (Abatacept) during production and/or at harvest level Furthermore, the present disclosure also reduces and/or decreases low molecular weight species (LMWs) and improves titer of the fusion protein during the mammalian cell culture.[French]
La présente divulgation concerne un procédé amélioré permettant de maîtriser des paramètres de qualité de produit choisis parmi un profil de sialylation totale et un pourcentage de pic principal accru de la protéine de fusion Fc particulièrement CTLA4-IgG (Abatacept) pendant la production et/ou à la récolte. En outre, la présente divulgation réduit et/ou diminue les espèces de faible poids moléculaire (LMW) et améliore le titre de la protéine de fusion pendant la culture de cellules de mammifère.